Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation

Table 2

Survival outcomes.

Study	NRM		Relapse		PFS or DFS		OS
	Haplo	Matched; (MRD/MUD)	Haplo	Matched; (MRD/MUD)	Haplo	Matched; (MRD/MUD)	Haplo	Matched; (MRD/MUD)
McCurdy et al. Blood 2015 [11]	1 yr: 11%		3 yr: 46%		3 yr: 40%		3 yr: 50%
			Low: 20%		Low: 65%	66%	Low: 73%	70%
			Int: 48%		Int: 39%	31%	Int: 49%	47%
			High: 67%		High: 25%	15%	High: 37%	25%
Ciurea et al. Blood 2015 [6]	MAC:		MAC:				MAC:
	1 yr: 12%	14%	3 yr: 44%	39%			3 yr: 45%	50%
	RIC:		RIC:				RIC:
	1 yr: 6%	16%	3 yr: 58%	42%			3 yr: 46%	44%
Bashey et al. BBMT 2015 [7]	2 yr: 17%	(14%/16%)	2 yr: 29%	(30%/34%)	2 yr: 54%	(56%/50%)	2 yr: 57%	(72%/59%)
Raiola et al. BBMT 2014 [3]	D1000: 18%	(24%/33%)	35%	(40%/23%)	4 yr: 43%	(32%/36%)	4 yr: 52%	(45%/43%)
Bashey et al. JCO 2013 [5]	1 yr: 4%	(10%/10%)	2 yr: 33%	(34%/34%)	2 yr: 60%	(53%/52%)	2 yr: 64%	(76%/67%)
Di Stasi et al. BBMT 2014 [4]	1 yr: 24%	(20%/35%)	1 yr: 33%	(28%/23%)	3 yr: 30%	(36%/27%)
Kanakry et al.; BBMT 2013 [10]	1 yr: 8%	MRD 6%	1 yr: 34%	MRD 38%
Burroughs et al. BBMT 2008 [2]	2 yr: 9%	(21%/8%)	2 yr: 40%	(56%/63%)	2 yr: 51%	(23%/29%)	2 yr: 58%	(53%/58%)

NRM: nonrelapse mortality; haplo: human leukocyte antigen- (HLA-) haploidentical; matched: HLA-matched; MRD: HLA-matched related donor; MUD: HLA-matched unrelated donor; PFS: progression-free survival; DFS: disease-free survival; OS: overall survival; yr: year; low: low risk by disease risk index; Int: intermediate risk by disease risk index; high: high or very high risk by disease risk index; BBMT: biology of blood and marrow transplantation; D: day; JCO: Journal of Clinical Oncology.
Data based on 614 recipients of reduced intensity conditioning and HLA-matched stem cell transplantation from the original disease risk index study cohort [12] whose outcomes were tabulated and received from P. Armand Dana-Farber Cancer Institute, email, July 24, 2014, personal communication.